Cargando…
Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice
BACKGROUND: Previously, we demonstrated the therapeutic efficacy of a human papillomavirus (HPV) vaccine, including HPV16 E7 peptide and CpG oligodeoxynucleotides (CpG ODN), against small TC-1 grafted tumors. Here, we developed an HPV16 E7 peptide and CpG ODN vaccine delivered using liposomes modifi...
Autores principales: | Zhao, Yan, Wang, Huan, Yang, Yang, Jia, Wendan, Su, Tong, Che, Yuxin, Feng, Yixin, Yuan, Xuemei, Wang, Xuelian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718974/ https://www.ncbi.nlm.nih.gov/pubmed/33293808 http://dx.doi.org/10.2147/IJN.S275670 |
Ejemplares similares
-
Inhibition of Orthotopic Genital Cancer Induced by Subcutaneous Administration of Human Papillomavirus Peptide Vaccine with CpG Oligodeoxynucleotides as an Adjuvant in Mice
por: Wang, Huan, et al.
Publicado: (2021) -
Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice [Corrigendum]
Publicado: (2021) -
CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015) -
Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA Vaccines
por: Šmahel, Michal, et al.
Publicado: (2011) -
CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody
por: Hiramatsu, Kosuke, et al.
Publicado: (2015)